IBI363
-
ASCO 2025: Innovent Presents Phase 1/2 Data for IBI363, a First-in-Class PD-1/IL-2α Bispecific Antibody, in Immunotherapy-Refractory Advanced Melanoma
Innovent Biologics announced positive Phase 1/2 data for IBI363, a PD-1/IL-2α-bias bispecific antibody, at ASCO 2025. The study showed promising results in immunotherapy-resistant acral and mucosal melanoma (“cold tumors”), demonstrating a 23.3% confirmed objective response rate and 14.8 months median overall survival. A Phase 2 registration trial for IBI363 is underway, offering a potential breakthrough for advanced melanoma treatment.
